Skip to main content
. 2015 Jan 12;6:6047. doi: 10.1038/ncomms7047

Figure 4. IL-6 secretion from adipocytes by a cAMP/p38-dependent pathway in vitro.

Figure 4

(a) Il6 expression in 3T3-L1 adipocytes after amlexanox treatment (n=3 wells per treatment per time point). (b) IL-6 secretion from 3T3-L1 adipocytes after amlexanox treatment (n=3 wells per treatment per time point). (c) cAMP in 3T3-L1 adipocytes treated with amlexanox for 5, 15, 30, 60 and 120 min (n=3 wells per treatment per time point). (d) Immunoblot analysis of Stat3, TBK1 and p38 phosphorylation in 3T3-L1 adipocytes treated with amlexanox for indicated times. RalA serves as loading control. (e) Il6 expression in 3T3-L1 adipocytes after amlexanox treatment with and without pre-treatment with SB203,580 (n=3 wells per treatment per time point). (f) IL-6 secretion from 3T3-L1 adipocytes after amlexanox treatment with and without pre-treatment with SB203,580 (n=3 wells per treatment per time point). * indicates P value<0.05 (student’s t-test a–c or two-way ANOVA plus Tukey–Krammer post-hoc analysis e,f) amlexanox treated versus vehicle control. # indicates P value<0.05 (two-way ANOVA plus Tukey–Krammer post-hoc analysis) amlexanox, SB203,580 treated versus amlexanox only. Error bars presented as s.e.m.